Halozyme Therapeutics, Inc. (HALO) Tops Q2 EPS by 2c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $71.15 +2.20%
EPS Growth %: +17.5%
Financial Fact:
Net income (loss): -28.95M
Today's EPS Names:
DTGI, CRMT, MAYS, More
EPS Growth %: +17.5%
Financial Fact:
Net income (loss): -28.95M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported Q2 EPS of ($0.13), $0.02 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $7.8 million versus the consensus estimate of $5.63 million.
For earnings history and earnings-related data on Halozyme Therapeutics, Inc. (HALO) click here.
For earnings history and earnings-related data on Halozyme Therapeutics, Inc. (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Worthington Steel, Inc. (WS) Misses Q4 EPS by 3c
- Raymond James Starts Tonix Pharma (TNXP) at Strong Buy
- H.B. Fuller (FUL) Tops Q2 EPS by 3c; Offers Outlook
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
